Imatinib mesylate: Past successes and future challenges in the treatment of gastrointestinal stromal tumors

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 365-379

  Ksienski, Doran ^a  

^a Victoria Island Cancer Center   (Canada)

Author keywords

Adjuvant; Gastrointestinal stromal tumor; Imatinib; Metastatic

Indexed keywords

IMATINIB; NILOTINIB; PLACEBO; RETASPIMYCIN; SORAFENIB; SUNITINIB;

ADVANCED CANCER; ANEMIA; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG FATALITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; KIT GENE; METASTASIS; NAUSEA; NEUTROPENIA; PDGFRA GENE; RASH; REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 84855268036     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S4259     Document Type: Review

References (88)

1. Nilsson B, Bümming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B. Gastrointestinal stromal tumors: the incidence, prevelance, clinical course and prognostication in the preimatinib mesylate era-a population based study in western Sweden. Cancer. 2005;15(4):821-9.
2. Laurini JA, Carter JE. Gastrointestinal stromal tumors: A review of the literature. Archives Pathology Laboratory Medicine. 2010;134:134-41.
3. Clary BM, Dematteo RP, Lewis JJ, Leung D, Brennan M. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperito-neum: a clinical comparison. Annals of Surgical Oncology. 2001;8(4): 290-9.
4. Agaram NP, Laquaglia MP, Ustun B, Gui T, Wong G, Socci N. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008;14:3204-15.
5. Dematteo R, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumours: Before and after STI-571. Human Pathology. 2002;33(5):466-77.
6. Blanke CD, Corless CL. State-of-the art therapy for gastrointestinal stromal tumours. Cancer Investigation. 2005;23:274-80.
7. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg G, Flethcher JA. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresect-able or metastatic gastrointestinal stromal tumors expressing KIT. Journal of Clinical Oncology. 2008;26:620-5.
8. Yuzawa S, Opatowsky Y, Zhang Z, Mandiyan V, Lax I, Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by Stem cell factor. Cell. 2007;130(2):323-34.
9. Safdar A, Sher A. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumours (GIST). Gene. 2007;401:38-45.
10. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours. Science. 1998;279:577-80.
11. Corless CL, Schroeder A, Griffth D, et al. PDGFRA mutations in gastrointestinal stromal tumours: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:5357-64.
12. Blay J Y. New paradigms in gastrointestinal stromal tumour management. Annals of Oncology. 2009;20(Suppl 1):i18-24.
13. Trent JC, Dupart J, Zhang W. Imatinib mesylate: targeted therapy of gastrointestinal stromal tumor. Current Cancer Therapy Reviews. 2005;1: 93-108.
14. Zhang L, Smyrk TC, Young WF, Stratakis CA, Carney JA. Gastric stromal tumors in carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: fndings in 104 cases. American Journal of Surgical Pathology. 2010;34:53-64.
15. Gill A, Chou A, Villain R, Adele C, Lui M, Jin R. Immunohistochemistry for SDHB divides gastrointestinal. American journal of surgical pathology stromal tumors (GISTs) into 2 distinct types. The American Journal of Surgical Pathology. 2010;34:636-44.
16. Janeway KA, Kim SY, Lodish M, Nose V, Rustin P, Gaal J. Defects in suc-cinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011;108:314-8.
17. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348: 994-1004.
18. Heinrich MC, Griffth DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96(3):925-32.
19. Hornick JL, Fletcher C. The role of KIT in the management of patients with gastrointestinal stromal tumors. Human Pathology. 2007;38:679-87.
20. Leveque D, Maloisel F. Clinical pharmacokinetics of imatinib mesylate. In Vivo. 2005;19:77-84.
21. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology. 2004; 22(5):935-42.
22. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Reviews. 2009;35:692-706.
23. Delbaldo C, Chatelut E, Druker B, Talpaz M, Capdeville R. Pharmacokinetic-pharmacodynamic relationships of imatiniband its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2006;12(20):6073-8.
24. Kogel CE, Schellens JH. Imatinib. The Oncologist. 2007;12:1390-4.
25. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs. 2003;63:513-22.
26. Peng B, Lloyd P, Schren H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
27. Novartis Pharmaceuticals Corporation. Product information (US): Gleevec R (imatinib mesylate) tablets 100 and 400 mg [online]. Available from: http:// www.fda.gov/cder. Accessed October 1, 2011.
28. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Gross G. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos. 2005;33(10):1503-2.
29. Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. British Journal of Clinical Pharmacology. 2005;60:35-44.
30. Gibbons J, Egorin ML, Ramanathan RK, Fu P, Mulkerin DL, Shibata S. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008;26:570-6.
31. Ramanathan RK, Egorin MJ, Takimoto M, Remick C, Doroshow J, Lorusso P. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the national cancer institute organ dysfunction working group. J Clin Oncol. 2008;26:563-9.
32. Desai J. Response assessment in gastrointestinal stromal tumor. International Journal of Cancer. 2010;128:1251-8.
33. Van den Abbeele AD. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2001;20:362a.
34. Benjamin RS, Choi H, Macapinlac HA. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760-4.
35. Choi H, Charnsangavej C, Faria S, Tamm E, Benjamin R, Johnson M. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET fndings. AJR Am J Roentgenol. 2004;183:1619-28.
36. Tuveson DA, Willis NA, Jacks T, Singer S, Demetri D. STI571 inactiva-tion of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001;20(36):5054-8.
37. Joensuu H, Roberts P, Sarlomo-Rikala M, Andersson L, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New England Journal of Medicine. 2001;344(14):1052-6.
38. van Oosterom A, Judson I, Verweij J, Stroobants S, Nielson S. Safety and effcacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358(9291):1421-3.
39. Verweij J, van OA, Blay J Y, Judson I, Rodenhuis S, van der Graaf W. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC soft tissue and bone sarcoma group phase II study. Eur J Cancer. 2003;39:2006-11.
40. Doi T, Nishida T, Hirota T. Phase II clinical study of STI571 in Japanese (Jpn) patients (pts) with malignant gastrointestinal stromal tumors (GIST): Results of the B 1201study. J Clin Oncol. 2004;22(14S):4078.
41. Von Mehren M, Heinrich MC, Joensuu H, Blanke CD, Wehrle E, Demetri GD. Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). J Clin Oncol. 2011;29 Suppl 1: Abstr 10016.
42. Heinrich MC, Corless CL, Demetri GD. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342-9.
43. Dagher R, Cohen M, Williams G. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal-stromaltumors. Clin Cancer Res. 2002;8(3034):845.
44. European medicines association. Glivec: european public assessment report; 2001.
45. Blanke CD, Rankin C, Demetri GD, Christopher WR, von Mehren M, Benjamin RS. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626-32.
46. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY. Progression free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127-34.
47. Heinrich MC, Owza K, Corles CL, Hollis D, Borden EC, Fletcher CD. Correlation of kinase genotype and clinical outcome in the north american intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by cancer and leukemia group B and southwest oncology group. J Clin Oncol. 2008;26(33):5360-7.
48. Casali PG, Verweij J, Kotasek D. Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the EORTC ISG AGITG randomized trial in 946 patients. European Journal of Cancer Supplements. 2005:Abstr 711.
49. Debiec-Rychter M, Sciot R, le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;43: 1093-103.
50. Gastrointestinal stromal tumor Meta-analysis group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. Journal of Clinical Oncology. 2010;28(7):1247-53.
51. Casali PG, Blay JY. On behalf of the ESMO guidelines working group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2010:21 Suppl 5.
52. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™: Soft Tissue Sarcoma. http://www.nccn.org/index.asp. Accessed August 1, 2011.
53. DeMatteo RP, Lewis JL, Leung D, Muddan Woodruff JM, Brennan FM. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals of Surgery. 2000;231:51-7.
54. Gold JS, Gönen M, Gutiérrez A, Broto JM, del-Muro X, Smyrck TC. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10: 1045-52.
55. Nilsson B, Sjo K, Kindblom LG, Meis-Kidblom JM, Bumming P, Nilsson O. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). British Journal of Cancer. 2007;96:1656-8.
56. DeMatteo RP, Ballman K V, Antonescu CR, Maki RG, Pisters PW, Demetri GD. Placebo-controlled randomized trial of adjuvant imatinib mesylate following the resection of localized, primary gastrointestinal stromal tumor (GIST). Lancet. 2009;373(9669):1097-104.
57. European Medicines Association. Annex I: summary of product characteristics. Accessed August 1, 2011.
58. US Food and Drug Administration. Committee for medicinal products for human use post-authorisation summary of positive opinion for Glivec. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129210.htm; 2008. Accessed August 1, 2011.
59. Joensuu H, Eriksson M, Hatrmann J, et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol. 2011;29 Suppl:Abstr LBA1.
60. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Human Pathology. 2002;33(5):459-65.
61. McAuliffe JC, Hunt KK, Lazar AJ, Choi H, Qiao W, Thall P. A randomized, phase II study of preoperative plus postoperative imatinibin GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009;16:910-9.
62. Eisenberg BL, Harris J, Blanke CD, Demetri G, Heinrich MC, Watson JC. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42-7.
63. Blesius A, Cassier PA, François BF, Fayette J, Ray-Coquard I, Bui B. Neoadjuvantimatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer. 2011;11:72.
64. National Comprehensive Cancer Network (NCCN) guidelines. Available at: http://www.nccn.org. Accessed August 4, 2011.
65. Thanopoulou E, Judson I. The safety profle of imatinib in CML and GIST: long-term considerations. Archives of Toxicology. 2011;4:3-12.
66. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacoki-netic study over time. EORTC soft tissue and bone sarcoma group. Cancer Chemotherapy and Pharmacology. 2005;55(4):379-86.
67. van Glabbeke M, Verweij J, Casali PG, Simes J, Le Cesne A, Reichardt P. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian GastroIntestinal Trials Group (EORTC-ISG-AGITG). European Journal of Cancer. 2006;14(4):2277-85.
68. Collin M, McClelland GJ, Custer PL. Periorbitaledema secondary to imatinib mesylate. Clin Opthal. 2010;4:427-31.
69. Milojkovic D, Short K, Salisbury JR, Dose-limiting dermatological toxic-ity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. Leukemia. 2003;17:1414-6.
70. Kerkela R, Grazette L, Yacobi R, Illiescu C, Patten R, Beahm C. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908-16.
71. Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR. Imatinibdoes not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005. European Journal of Cancer. 2007;43(6):974-8.
72. Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, Lenihan DJ. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer. 2010;116(1):184-92.
73. Gounder MM, Maki RG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer chemotherapy and Pharmacology. 2011;67(1):S25-S43.
74. Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD. Imatinib plasma levels are correlated with clinical beneft in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27: 3141-7.
75. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. Journal of Clinical Oncology. 2006;24:4764-74.
76. Blay JY, Cesne AL, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond: the french sarcoma group. Journal of Clinical Oncology. 2007;25(9):1107-13.
77. Feng W, Henk H, Thomas T, Hatfeld GA, Goldberg GA, Cortes J. Compliance and persistency with imatinib. Journal of Clinical Oncology. 2006;24(18S):6038.
78. Shankar S, van Sonnenberg E, Desai J. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005;235:892-8.
79. Yeh CN, Chen TW, Tseng JW, Liu YY, Wang SY, Tsai CY. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. Journal of Surgical Oncology. 2010;102: 599-603.
80. Demetri GD, Heinrich MC, Fletcher AJ, Fletcher CD, Van den Abbeele AD. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009;15(18):5902-9.
81. Heinrich MC, Maki RG, Corles CL, Antonescu CR, Harlow A, Griffth D. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Journal of Clinical Oncology. 2008;28(33):5352-9.
82. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verwij J. Effcacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-38.
83. Blay JY, von Mehren M. Nilotinib: A novel, selective tyrosine kinase inhibitor. Seminars in Oncology. 2011;38(2):S3-9.
84. Reichardt P, Blay J, Gelderblom H, et al. Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): frst results from ENEST g3 [abstract]. J Clin Oncol. 2010;28:10017.
85. Ortiz AG, Salcedo JM. Heat shock proteins as targets in oncology. Clin Transl Oncol. 2010;12:166-73.
86. Demetri GD, Le Cesne A, von Mehren M, Chmielowski B, Bauer S, Chow WA. Final results from a phase III study of IPI-504 (retaspimy-cin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapies. Gastrointestinal Cancers Symposium. 2010:Abstr 64.
87. Stefan S, Wiemer E, Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST)-the solid tumor model for cancer-specifc treatment. Nature Clinical Practice Oncology. 2008;5:102-11.
88. DeMatteo RP, Owzar K, Antonescu CR, Maki R, Demetri GD, McCarter M. Effcacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The US Intergroup phase II trial ACOSOG Z9000. http://www.asco. org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID= 53&abstractID=10450. Accessed October 20, 2011.